IP Verse

Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or Hyperglycemia

Patent No. EP2396005 (titled "Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or Hyperglycemia") was filed by Boehringer Ingelheim on Feb 11, 2010. The application was issued on Nov 26, 2025.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BARDEHLE PAGENBERGAug 10, 2026BARDEHLE PAGENBERG SL
BRAND MURRAY FULLERAug 3, 2026BRAND MURRAY FULLER
BRAND MURRAY FULLER SERVICESAug 3, 2026BRAND MURRAY FULLER
GALENICUM HEALTH SLUJul 28, 2026GALENICUM HEALTH SLU
GENERICS UKJul 24, 2026TER MEER STEINMEISTER & PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2396005

BOEHRINGER INGELHEIM
Application Number
EP10703287A
Filing Date
Feb 11, 2010
Status
Granted And Under Opposition
Oct 24, 2025
Publication Date
Nov 26, 2025
External Links
Slate, Register , Google Patents